Radiolabeled Liposomes for Bone Marrow Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeted drug delivery to bone marrow are inefficient, leading to high concentrations and frequent administrations, which can result in unintended delivery to tumor tissues, reducing treatment efficacy and causing side effects, while existing imaging techniques lack high-resolution quantification for drug distribution in the reticuloendothelial system.
Innovation Solution
Development of liposome-based nanocarriers with a negative charge and specific lipid composition, labeled with isotopes and chelators for PET imaging, which selectively target bone marrow and lymph nodes, minimizing tumor delivery and allowing for high-resolution, quantitative imaging and drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high concentrations of radioprotective agents are administered to ensure adequate delivery to bone marrow, then bone marrow protection is improved, but unintended delivery to tumor tissue increases, reducing treatment efficacy
Solution Approach 1:
The patent applies local quality by modifying the surface properties of liposomes to have a negative charge, which specifically interacts with bone marrow tissue. This creates a localized targeting effect where the radioprotective agent is delivered preferentially to bone marrow rather than distributed systemically, thereby protecting the marrow without increasing tumor exposure
Solution Approach 2:
The patent uses liposomes as an intermediary carrier system. These liposomal nanocarriers encapsulate the radioprotective agent and facilitate its selective transport to bone marrow tissue. The liposome acts as a mediator that enables targeted delivery, allowing adequate drug concentrations to reach the marrow without requiring high systemic doses that would otherwise contaminate tumor tissue
2Duration of action of moving object
If frequent administrations of radioprotective agents are performed to maintain cytoprotective concentrations in bone marrow, then bone marrow protection is improved, but treatment complexity and side effects increase
Solution Approach 1:
The patent employs dynamic targeting where the liposomal nanocarriers continuously circulate and dynamically interact with bone marrow tissue over time. The negative surface charge enables ongoing selective uptake by bone marrow cells, maintaining protective drug concentrations throughout the treatment period without requiring repeated dosing. This dynamic process adapts to the pharmacokinetics of the system, sustaining therapeutic levels naturally
Solution Approach 2:
The patent achieves continuous useful action through the sustained targeting capability of the liposomal formulation. The radioprotective agent is delivered continuously to bone marrow tissue as the liposomes circulate and are progressively taken up by marrow cells. This continuous delivery mechanism maintains cytoprotective concentrations throughout the radiation therapy course, eliminating the need for frequent discrete administrations
3Quantity of substance
If radioprotective agents are delivered systemically to bone marrow, then bone marrow protection is achieved, but delivery to non-target tissues including tumor increases, causing unfavorable consequences
Solution Approach 1:
The patent applies local quality by endowing the liposome surface with a negative charge that specifically recognizes and binds to bone marrow tissue. This localized chemical property enables the carrier to differentiate between target and non-target tissues, delivering the radioprotective agent exclusively to bone marrow while leaving tumor and other tissues unaffected
Solution Approach 2:
The liposomal nanocarrier serves as an intermediary that decouples the delivery route from the distribution pattern. Although administered systemically, the liposome mediator controls the subsequent biodistribution through its surface properties, ensuring that the radioprotective agent is released only at the bone marrow site rather than distributing freely to all tissues including tumors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposome-based nanocarriers achieve selective and high-concentration drug delivery to bone marrow with minimal tumor uptake, enabling effective radioprotection and imaging, thereby enhancing the therapeutic index and reducing side effects.
Implementation Method 1
PET-traceable liposomal nanocarriers for imaging tissue
Data Source
AI summary
Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., livers. Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure of the individual.